Absci (ABSI) EBT Margin (2020 - 2026)
Absci (ABSI) posted EBT Margin of 13758.6% for Q1 2026, down 200.87% sequentially from 4572.92% in Q4 2025, and down 1152366.0% YoY from N/an in Q1 2025.
Powered by 
Analysis
Absci (ABSI) EBT Margin (2020 - 2026) Analysis & Trends
Absci has reported EBT Margin for 7 years, with the latest figure at 13758.6% in Q1 2026.
- Quarterly EBT Margin fell 1152366.0% year-over-year to 13758.6% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6445.81% (down 421480.0% YoY) and the FY2025 annual result came in at 4111.21%, down 183870.0% from the prior year.
- EBT Margin fell to 13758.6% in Q1 2026 per ABSI's latest filing, from 4572.92% in the prior quarter.
- Over five years, EBT Margin peaked at 1237.33% in Q2 2023 and troughed at 13758.6% in Q1 2026.
- A 5-year average of 4755.85% and a median of 4355.19% in 2024 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2022 and 2026: EBT Margin soared 945100 bps in 2022, then tumbled 1152366 bps in 2026.
- Over 5 years, EBT Margin stood at 5891.15% in 2022, then decreased by 18 bps to 6951.78% in 2023, then soared by 37 bps to 4355.19% in 2024, then retreated by 5 bps to 4572.92% in 2025, then sank by 201 bps to 13758.6% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 13758.6%, 4572.92%, and 7566.67% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Absci | 1.39 Bn | 1.19 Bn | - | -10,430.82% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -10,430.82% |
| Mar 31, 2026 | -13,758.60% |
| Dec 31, 2025 | -4,572.92% |
| Sep 30, 2025 | -7,566.67% |
| Jun 30, 2025 | -5,132.88% |
| Mar 31, 2025 | -2,234.94% |
| Dec 31, 2024 | -4,355.19% |
| Sep 30, 2024 | -1,608.52% |
| Jun 30, 2024 | -1,948.82% |
| Mar 31, 2024 | -2,445.77% |
| Dec 31, 2023 | -6,951.78% |
| Sep 30, 2023 | -2,951.61% |
| Jun 30, 2023 | -1,237.33% |
| Mar 31, 2023 | -1,839.87% |
| Dec 31, 2022 | -1,282.66% |
| Sep 30, 2022 | -1,163.82% |
| Jun 30, 2022 | -2,889.22% |
| Mar 31, 2022 | -3,525.40% |
| Dec 31, 2021 | -1,809.09% |
| Sep 30, 2021 | -1,646.33% |